Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Forest Baskett Insider Profile
11 Followers
Forest Baskett, Ten Percent Owner at Tesaro, holds 3.61M shares in MBX Biosciences, Inc. (Ticker: MBX), holds 1.09M shares in Korro Bio (Ticker: KRRO), holds 3.01M shares in Sagimet Biosciences, Inc. Class A (Ticker: SGMT).
Profitable Transactions
28 out of 100 Profitable Transactions
Average Return
-23.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Forest Baskett holds in companies
Most Profitable Insider Trade
Stock:
Achaogen
(AKAOQ)
(AKAOQ)
Rating:Informative Buy
Date:Jun 07, 2016 - Jun 07, 2017
Return:+423.70%
The most profitable trade made by Forest Baskett
Forest Baskett's Trading History
Tesaro
Jan 22, 2019
―
Uninformative Sell
781.54M
$0.00
Adaptimmune Therapeutics
Jan 28, 2020
Ten Percent Owner
Informative Buy
4.95M
$61.90M
AVEO Pharma
Oct 21, 2022
―
Uninformative Buy
―
$48.30K
Achaogen
Dec 19, 2016
―
Informative Buy
6.75M
$117.88K
Cascadian Therapeutics
Mar 13, 2018
―
Uninformative Sell
―
$0.00
Regulus
May 09, 2019
Former 10% Owner
Informative Buy
1.23M
$3.26M
Appian
Feb 15, 2018
Ten Percent Owner
Uninformative Buy
―
$561.87K
Synlogic
Jan 26, 2018
Ten Percent Owner
Uninformative Buy
4.00M
$6.01M
Surface Oncology
Apr 23, 2018
―
Informative Buy
2.00M
$3.54M
Mulesoft Inc
May 09, 2018
―
Uninformative Sell
―
$0.00
Liquidia Technologies
Aug 01, 2018
Ten Percent Owner
Uninformative Buy
―
$27.58M
Elastic
Oct 10, 2018
Ten Percent Owner
Uninformative Buy
―
$658.41M
Genocea Biosciences
May 26, 2022
Ten Percent Owner
Informative Sell
711.52K
$0.00
Trevi Therapeutics
Apr 13, 2022
Ten Percent Owner
Informative Buy
5.00M
$42.21M
Mirum Pharmaceuticals
Jun 15, 2023
Ten Percent Owner
Uninformative Buy
―
$90.82M
Mersana Therapeutics
Sep 16, 2020
Ten Percent Owner
Uninformative Buy
―
$9.55M
Cloudflare
Nov 13, 2020
Ten Percent Owner
Uninformative Buy
―
$432.98M
AKOUOS
Dec 02, 2022
―
Uninformative Sell
―
$0.00
Nkarta
Jul 16, 2020
Ten Percent Owner
Uninformative Buy
―
$6.88M
Inozyme Pharma
Jul 28, 2020
Ten Percent Owner
Uninformative Buy
―
$7.29M
Metacrine
Dec 27, 2021
―
Informative Sell
493.91K
$1.49M
Eargo
May 26, 2021
―
Uninformative Buy
―
$11.62M
Sprout Social
Nov 17, 2020
Ten Percent Owner
Uninformative Buy
―
$106.50M
Coursera
Feb 17, 2023
Ten Percent Owner
Uninformative Buy
―
$107.77M
Monte Rosa Therapeutics
Jun 30, 2021
Ten Percent Owner
Uninformative Buy
―
$53.31M
NeueHealth Inc
Jun 30, 2021
Ten Percent Owner
Uninformative Buy
―
$696.94M
Robinhood Markets
May 04, 2022
Director
Uninformative Buy
―
$914.54M
IonQ
Nov 18, 2022
Ten Percent Owner
Uninformative Buy
―
$649.61M
Arcellx Inc
Dec 22, 2022
Ten Percent Owner
Uninformative Buy
―
$358.46M
Savara
Jul 19, 2023
Ten Percent Owner
Informative Buy
1000.00K
$79.04M
Sagimet Biosciences, Inc. Class A
Jan 31, 2024
Ten Percent Owner
Uninformative Buy
―
$14.91M
Korro Bio
Apr 24, 2024
Ten Percent Owner
Informative Buy
999.99K
$47.63M
MBX Biosciences, Inc.
Sep 17, 2024
Ten Percent Owner
Uninformative Buy
―
$73.59M
Oruka Therapeutics
Feb 27, 2018
Ten Percent Owner
Informative Sell
730.10K
$0.00
Ardelyx
Dec 27, 2021
Ten Percent Owner
Informative Sell
3.63M
$51.82M
TRACON Pharmaceuticals
Mar 27, 2018
―
Informative Buy
1.91M
$110.91K
Supernus Pharmaceuticals
Nov 12, 2015
Ten Percent Owner
Uninformative Buy
―
$7.53M
Tableau
Dec 03, 2015
―
Uninformative Sell
―
$3.93M
Box
Jan 22, 2015
Ten Percent Owner
Informative Buy
―
$5.21M
Hyperion Therapeutics
May 11, 2015
―
Uninformative Sell
109.67M
―
Dermira
Oct 08, 2014
―
Uninformative Buy
―
$65.68M
Loxo Oncology
Aug 06, 2014
―
Uninformative Buy
―
$419.91M
Aerohive Networks
Apr 03, 2014
―
Uninformative Buy
―
$20.75M
Care
Nov 08, 2017
―
Uninformative Buy
―
$33.88M
Millennial Media
Oct 30, 2012
―
Informative Sell
21.47M
$14.34M
Epizyme
Jan 12, 2016
―
Informative Buy
10.00M
$9.20M
Sorrento Tech Inc
Jul 22, 2014
―
Uninformative Buy
―
$2.09M
Viracta Therapeutics
Aug 29, 2014
Ten Percent Owner
Informative Sell
2.13M
$978.46K
Workday
Apr 11, 2013
Ten Percent Owner
Uninformative Buy
―
$2.84M
Clovis Oncology
Jun 05, 2013
―
Uninformative Buy
―
$37.24
Groupon
Sep 17, 2013
Ten Percent Owner
Uninformative Buy
―
$429.10K
InnerWorkings
Mar 30, 2012
―
Uninformative Buy
―
$44.85K
Xoom Corp
Oct 31, 2013
―
Uninformative Buy
―
―
Echo Global Logistics
Mar 01, 2012
―
Uninformative Buy
―
$9.41K
Audience Inc
Dec 04, 2013
―
Informative Sell
8.80K
―
Fusion-IO
Jun 07, 2011
―
Informative Buy
―
―
Omthera
―
―
―
―
ChannelAdvisor
―
―
―
$0.00
List of latest transactions for each holding click on a transaction to see Forest Baskett's performance on stock
You May Also Like
Forest Baskett insider profile FAQ
What is the percentage of profitable transactions made by Forest Baskett?
The percentage of profitable transactions made by Forest Baskett is 28%.
What is the average return per transaction made by Forest Baskett?
The average return per transaction made by Forest Baskett is -23.40%.
What stocks does Forest Baskett hold?
Forest Baskett holds: TSRO, ADAP, AVEO, AKAOQ, CASC, RGLS, APPN, SYBX, SURF, MULE, LQDA, ESTC, GNCAQ, TRVI, MIRM, MRSN, NET, AKUS, NKTX, INZY, MTCR, EAR, SPT, COUR, GLUE, NEUE, HOOD, IONQ, ACLX, SVRA, SGMT, KRRO, MBX, ORKA, ARDX, TCON, SUPN, DATA, BOX, HPTX, ~DERM, LOXO, ~HIVE, CRCM, MM, EPZM, ROKA, VIRX, WDAY, CLVSQ, GRPN, INWK, XOOM, ECHO, ADNC, FIO, OMTH, ECOM stocks.
What was Forest Baskett’s latest transaction?
Forest Baskett latest transaction was an Uninformative Buy of ―.
What was Forest Baskett's most profitable transaction?
Forest Baskett’s most profitable transaction was an Informative Buy of AKAOQ stock on June 7, 2016. The return on the trade was 423.70%.
What is Forest Baskett's role in Tesaro?
Forest Baskett's role in Tesaro is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.